Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Morgan Stanley
MS
|
+$798M |
| 2 |
AT&T
T
|
+$527M |
| 3 |
Microchip Technology
MCHP
|
+$472M |
| 4 |
Netflix
NFLX
|
+$446M |
| 5 |
PNC Financial Services
PNC
|
+$444M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$694M |
| 2 |
KeyCorp
KEY
|
+$401M |
| 3 |
Deere & Co
DE
|
+$322M |
| 4 |
CSX Corp
CSX
|
+$318M |
| 5 |
NXP Semiconductors
NXPI
|
+$314M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 5.93% |
| 2 | Technology | 4.66% |
| 3 | Healthcare | 4.45% |
| 4 | Industrials | 4.14% |
| 5 | Consumer Discretionary | 3.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3376
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
| $3.43M | ﹤0.01% |
20,400
-1,100
| -5% | -$189K |
|
|
ESL
3377
DELISTED
Esterline Technologies
ESL
| $3.43M | ﹤0.01% |
37,712
-17,832
| -32% | -$1.5M |
|
3378
PUT
HealthEquity
HQY
$8.76B
| $3.43M | ﹤0.01% |
36,300
+3,700
| +11% | +$319K |
|
|
DOCU
3379
DocuSign
DOCU
$11.8B
| $3.42M | ﹤0.01% |
+65,077
| New | +$3.69M |
|
|
LOXO
3380
PUT
DELISTED
Loxo Oncology, Inc
LOXO
| $3.42M | ﹤0.01% |
20,000
-14,900
| -43% | -$2.5M |
|
3381
Yelp
YELP
$1.34B
| $3.42M | ﹤0.01% |
69,427
-361,928
| -84% | -$15.8M |
|
|
FPRX
3382
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $3.42M | ﹤0.01% |
245,335
+98,288
| +67% | +$1.46M |
|
3383
Starbucks
SBUX
$123B
| $3.41M | ﹤0.01% |
60,000
-1,322,579
| -96% | -$69.9M |
|
3384
CALL
Zscaler
ZS
$29.7B
| $3.4M | ﹤0.01% |
83,500
-85,700
| -51% | -$3.46M |
|
3385
PUT
Willis Towers Watson
WTW
$30.8B
| $3.4M | ﹤0.01% |
24,100
-8,200
| -25% | -$1.24M |
|
|
NAV
3386
PUT
DELISTED
Navistar International
NAV
| $3.4M | ﹤0.01% |
88,200
-66,900
| -43% | -$2.79M |
|
3387
CALL
Canadian National Railway
CNI
$76.7B
| $3.39M | ﹤0.01% |
37,800
+31,300
| +482% | +$2.73M |
|
3388
Marcus & Millichap
MMI
$1.2B
| $3.39M | ﹤0.01% |
97,707
+76,963
| +371% | +$2.92M |
|
|
AERI
3389
CALL
DELISTED
Aerie Pharmaceuticals
AERI
| $3.39M | ﹤0.01% |
55,100
+35,300
| +178% | +$2.27M |
|
3390
Unifirst Corp
UNF
$5.19B
| $3.39M | ﹤0.01% |
19,525
+15,766
| +419% | +$2.9M |
|
3391
Analog Devices
ADI
$190B
| $3.38M | ﹤0.01% |
36,612
-85,679
| -70% | -$8.23M |
|
3392
Chegg
CHGG
$87.5M
| $3.38M | ﹤0.01% |
118,980
-86,454
| -42% | -$2.58M |
|
3393
Murphy Oil
MUR
$4.96B
| $3.38M | ﹤0.01% |
101,429
+16,418
| +19% | +$522K |
|
|
NE
3394
PUT
DELISTED
Noble Corporation
NE
| $3.38M | ﹤0.01% |
481,000
+22,400
| +5% | +$136K |
|
3395
PUT
Acadia Pharmaceuticals
ACAD
$4.87B
| $3.38M | ﹤0.01% |
162,800
+58,100
| +55% | +$914K |
|
3396
iShares MSCI Europe Financials ETF
EUFN
$4.31B
| $3.38M | ﹤0.01% |
166,612
-581,068
| -78% | -$11.8M |
|
3397
PUT
Methanex
MEOH
$4.34B
| $3.38M | ﹤0.01% |
42,700
+29,600
| +226% | +$2.15M |
|
3398
PTC
PTC
$16.2B
| $3.38M | ﹤0.01% |
31,789
+2,597
| +9% | +$254K |
|
|
BERY
3399
DELISTED
Berry Global Group, Inc.
BERY
| $3.38M | ﹤0.01% |
75,954
-59,972
| -44% | -$2.63M |
|
|
ZUO
3400
DELISTED
Zuora, Inc.
ZUO
| $3.37M | ﹤0.01% |
145,816
+90,589
| +164% | +$2.42M |
|
Similar funds
Citadel Advisors's Q3 2018 Portfolio in Review
As of Q3 2018, Citadel Advisors held 10,190 positions worth $224B, up 10% from $203B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Citadel Advisors deployed $7.48B of net new capital in Q3 2018, opening 1,427 new positions and adding to 4,227 existing holdings. Its largest new stake was Alibaba: 1,030,311 shares worth $170M.
By sector, the portfolio is most concentrated in Financials at 5.9% of assets, down from 6.2% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Goldman Sachs, an estimated $694M trimmed.
- Citadel Advisors's largest Q3 2018 buy was Alibaba: 1,030,311 shares worth $170M.
- Citadel Advisors added most to Morgan Stanley in Q3 2018, an estimated $798M increase.
- Citadel Advisors's biggest Q3 2018 reduction was Goldman Sachs, cutting an estimated $694M.
- Citadel Advisors fully exited XL Group Ltd. in Q3 2018, selling an estimated $207M.
- Citadel Advisors's ten largest holdings make up 25% of its $224B portfolio in Q3 2018.
- Citadel Advisors opened 1,427 new positions and closed 1,043 in Q3 2018.
- Citadel Advisors's portfolio value rose 10% quarter-over-quarter to $224B.
Based on Citadel Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.